netFormulary
 Report : Medicines with links to NICE 20/10/2019 09:54:27

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Vedolizumab 01.05.03 Formulary NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
Vedolizumab 01.05.03 Formulary NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Abatacept 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abatacept 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abatacept 10.01.03 Restricted Use NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Abemaciclib tabs 08.01.05 Non Formulary NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Abemaciclib tabs 08.01.05 Non Formulary NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Abiraterone 08.03.04.02 Formulary NICE TA259: Abiraterone for castration resistant prostate cancer
Abiraterone 08.03.04.02 Formulary NICE TA387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Adalimumab 11.99.99.99 Formulary NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
Adalimumab 01.05.03 Formulary NICE TA187: Crohn’s disease - infliximab and adalimumab
Adalimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Adalimumab 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Adalimumab 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Adalimumab 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Adalimumab 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Adalimumab 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis
Adalimumab 13.05.03 Restricted Use NICE TA146: Adalimumab for the treatment of adults with psoriasis
Adalimumab 13.05.03 Restricted Use NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab 13.05.03 Restricted Use NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Adefovir Dipivoxil 05.03.03.01 Restricted Use NICE TA96: Hep B - adefovir dipivoxil and pegylated interferon alpha-2a
Adenosine deaminase (ADA) cDNA sequence 17 Non Formulary NICE HST7: Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency
Afatinib 08.01.05 Restricted Use NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Afatinib 08.01.05 Restricted Use NICE TA444 (not recommended): Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)
Aflibercept infusion 08.01.05 Formulary NICE TA307 (not recommended): Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Aflibercept intraocular injection 11.08.02 Restricted Use NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Aflibercept intraocular injection 11.08.02 Restricted Use NICE TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration
Aflibercept intraocular injection 11.08.02 Restricted Use NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Aflibercept intraocular injection 11.08.02 Restricted Use NICE TA346: Aflibercept for treating diabetic macular oedema
Aflibercept intraocular injection 11.08.02 Restricted Use NICE TA486: Aflibercept for treating choroidal neovascularisation
Agomelatine 04.03.04 Non Formulary NICE TA231 (not recommended): Agomelatine for the treatment of major depressive episodes (terminated appraisal)
Alectinib tabs 08.01.05 Formulary NICE TA438 (not recommended): Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)
Alectinib tabs 08.01.05 Formulary NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
Alemtuzumab 08.02.04 Restricted Use NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis
Alendronic Acid 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Alirocumab 02.12 Restricted Use NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Formulary NICE TA177: Alitretinoin for the treatment of severe chronic hand eczema
Alteplase 02.10.02 Restricted Use NICE TA264: Ischaemic stroke (acute) - alteplase
Amantadine 05.03.04 Restricted Use NICE TA168 (amantadine NOT recommended): Amantadine, oseltamivir and zanamivir for the treatment of influenza
Amantadine 05.03.04 Restricted Use NICE TA158 (amantadine NOT recommended): Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Anastrozole 08.03.04.01 Restricted Use NICE TA112: Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
Anti-D (Rh0) Immunoglobulin 14.05.03 Restricted Use NICE TA156: Anti-D in pregnant women
Antithymocyte immunoglobulin - rabbit 08.02.02 Restricted Use NICE TA481 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in adults
Antithymocyte immunoglobulin - rabbit 08.02.02 Restricted Use NICE TA482 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in children and young people
Apixaban 02.08.02 Restricted Use NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apixaban 02.08.02 Restricted Use NICE TA275: Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation
Apixaban 02.08.02 Restricted Use NICE TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
Apremilast 10.01.03 Restricted Use NICE TA433: Apremilast for treating active psoriatic arthritis
Apremilast 13.05.03 Restricted Use NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
Aripiprazole 04.02.01 Restricted Use NICE TA292: Bipolar disorder (children) - aripiprazole
Aripiprazole 04.02.01 Restricted Use NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years
Arsenic Trioxide 08.01.05 Restricted Use NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
Aspirin 02.09 Formulary NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Atezolizumab 08.01.05 Formulary NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Atezolizumab 08.01.05 Formulary NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Atezolizumab 08.01.05 Formulary NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Atezolizumab 08.01.05 Formulary NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
Atomoxetine 04.04 Restricted Use NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents
Autologous chondrocyte implantation using chondrosphere 17 Non Formulary NICE TA508: Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee
Avelumab 08.01.05 Restricted Use TA517: Avelumab for treating metastatic Merkel cell carcinoma
Axicabtagene ciloleucel infusion 08.01.05 Non Formulary NICE TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
Axitinib 08.01.05 Restricted Use NICE TA333: Axitinib for advanced renal cell carcinoma
Azacitidine 08.01.03 Restricted Use NICE TA218: azacitidine for myelodysplastic syndromes
Azacitidine 08.01.03 Restricted Use NICE TA399 (not recommended): Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
Baricitinib 10.01.03 Restricted Use NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
Basiliximab 08.02.02 Restricted Use NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Basiliximab 08.02.02 Restricted Use NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Bee and Wasp Allergen Extracts 03.04.02 Restricted Use NICE TA246: Pharmalgen for the treatment of bee and wasp venom allergy
Belatacept 08.02.02 Non Formulary NICE TA481 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in adults
Belatacept 08.02.02 Non Formulary NICE TA482 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in children and young people
Belimumab 10.01 Formulary NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Bendamustine 08.01.01 Restricted Use NICE TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia
Bendamustine 08.01.01 Restricted Use NICE TA206 (not recommended): Bendamustine for the treatment of indolent (low grade) non-Hodgkin’s lymphoma that is refractory to rituximab (terminated appraisal)
Benralizumab injection 03.04.02 Non Formulary NICE TA565: Benralizumab for treating severe eosinophilic asthma
Bevacizumab 08.01.05 Restricted Use NICE TA263 (not recommended): Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
Bevacizumab 08.01.05 Restricted Use NICE TA285 (not recommended): Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
Bevacizumab 08.01.05 Restricted Use NICE TA214 (not recommended): Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer
Bevacizumab 08.01.05 Restricted Use NICE TA242 (not recommended): Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy
Bevacizumab 08.01.05 Restricted Use NICE TA118 (not recommended): Bevacizumab for the treatment of metastatic colorectal cancer
Bevacizumab 08.01.05 Restricted Use NICE TA353 (not recommended): Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)
Bevacizumab 08.01.05 Restricted Use NICE TA436 (not recommended): Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)
Bevacizumab 08.01.05 Restricted Use NICE TA148 (not recommended): Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal)
Bevacizumab 08.01.05 Restricted Use NICE TA178 (not recommended): Bevacizumab (1st line), sorafenib, sunitinib (2nd line) and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma
Bevacizumab 08.01.05 Restricted Use NICE TA212 (not recommended): Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
Bevacizumab 08.01.05 Restricted Use NICE TA284 (not recommended): Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Binimetinib tabs 08.01.05 Restricted Use NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Bivalirudin 02.08.01 Restricted Use NICE TA230: Bivalirudin for the treatment of ST-segment-elevation myocardial infarction (STEMI)
Blinatumomab 08.02.03 Non Formulary NICE TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Boceprevir 05.03.03.02 Non Formulary NICE TA253: hepatitis
Bortezomib injection 08.01.05 Restricted Use NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Bortezomib injection 08.01.05 Restricted Use NICE TA129: Multiple myeloma - bortezomib
Bortezomib injection 08.01.05 Restricted Use NICE TA311: Bortezomib for induction therapy in multiple myeloma
Bortezomib injection 08.01.05 Restricted Use NICE TA228: 1st line treatment of multiple myeloma
Bortezomib injection 08.01.05 Restricted Use NICE TA453 (not recommended): Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal)
Bortezomib injection 08.01.05 Restricted Use NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Bosutinib 08.01.05 Restricted Use NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
Bosutinib 08.01.05 Restricted Use NICE TA576 (not recommended): Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal)
Botulinum Toxin Type A 04.07.04.02 Formulary NICE TA260: Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Brentuximab vedotin 08.01.05 Restricted Use NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Brentuximab vedotin 08.01.05 Restricted Use NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brentuximab vedotin 08.01.05 Restricted Use NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
Brigatinib tabs 08.01.05 Formulary NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
Brodalumab 13.05.03 Restricted Use NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis
Buprenorphine sublingual tablets 04.10.03 Formulary NICE TA114: Drug misuse - methadone and buprenorphine
Cabazitaxel 08.01.05 Restricted Use NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cabozantinib caps 08.01.05 Formulary NICE TA516: Cabozantinib for treating medullary thyroid cancer
Cabozantinib tabs 08.01.05 Restricted Use NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Cabozantinib tabs 08.01.05 Restricted Use NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
Canagliflozin 06.01.02.03 Restricted Use NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Canagliflozin 06.01.02.03 Restricted Use NICE TA315: Canagliflozin for type 2 diabetes
Canakinumab 08.02.04 Restricted Use NICE TA281 (not recommended): Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal)
Canakinumab 08.02.04 Restricted Use NICE TA302 (not recommended): Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal)
Cangrelor 02.09 Restricted Use NICE TA351 (not recommended): Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal)
Capecitabine 08.01.03 Formulary NICE TA191: Gastric cancer (advanced) - capecitabine
Capecitabine 08.01.03 Formulary NICE TA61: Capecitabine and tegafur with uracil for metastatic colorectal cancer
Capecitabine 08.01.03 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Carfilzomib 08.01.05 Restricted Use NICE TA457: Carfilzomib for previously treated multiple myeloma
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Carmustine implant 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Carmustine implant 08.01.01 Non Formulary NICE TA149 (not recommended): Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal)
Cenegermin 20micrograms/ml eye drops 11.99.99.99 Non Formulary NICE TA532 (not recommended): Cenegermin for treating neurotrophic keratitis
Ceritinib 08.01.05 Restricted Use NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Ceritinib 08.01.05 Restricted Use NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
Certolizumab pegol 13.05.03 Non Formulary NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis
Certolizumab pegol 10.01.03 Restricted Use NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Certolizumab pegol 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Certolizumab pegol 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Certolizumab pegol 10.01.03 Restricted Use NICE TA445 : Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARD
Cetuximab 08.01.05 Restricted Use NICE TA145: Head and neck cancer - cetuximab
Cetuximab 08.01.05 Restricted Use NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Cetuximab 08.01.05 Restricted Use NICE TA242 (not recommended): Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy
Cetuximab 08.01.05 Restricted Use NICE TA472: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
Ciclosporin 0.1% eye drops 11.99.99.99 Restricted Use NICE TA369: Ciclosporin for treating eye disease that has not improved despite treatment with artificial tears
Cilostazol 02.06.04 Non Formulary NICE TA223 (not recommended): Intermittent claudication drugs
Cinacalcet 09.05.01.02 Restricted Use NICE TA117: Hyperparathyroidism - cinacalcet
Cladribine tablets 08.02.04 Restricted Use NICE TA493: Cladribine tablets for treating relapsing–remitting multiple sclerosis
Clopidogrel 02.09 Formulary NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Cobimetinib 08.02.04 Formulary NICE TA414 (not recommended): Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Colistimethate inhaler 05.01.07 Non Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Collagenase injection 10.03.01 Non Formulary NICE TA459: Collagenase clostridium histolyticum for treating Dupuytren’s contracture
Crizotinib 08.01.05 Restricted Use NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Restricted Use NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance
Crizotinib 08.01.05 Restricted Use NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Cytarabine–daunorubicin liposomal injection 08.01.03 Non Formulary NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
Dabigatran 02.08.02 Restricted Use NICE TA249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation
Dabigatran 02.08.02 Restricted Use NICE TA157: Dabigatran etexilate for the prevention of venous thromboembolism (VTE) after hip or knee replacement surgery in adults
Dabigatran 02.08.02 Restricted Use NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabrafenib caps 08.01.05 Restricted Use NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Dabrafenib caps 08.01.05 Restricted Use NICE TA321:Dabrafenib for BRAF V600 +ve melanoma
Dabrafenib caps 08.01.05 Restricted Use NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Daclatasvir 05.03.03.02 Restricted Use NICE TA364: Daclatasvir for treating chronic hepatitis C
Daclizumab 08.02.04 Restricted Use NICE TA441 : Daclizumab for treating relapsing–remitting multiple sclerosis
Dapagliflozin 06.01.02.03 Restricted Use NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Restricted Use NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Restricted Use NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Daratumumab injection 08.02.04 Restricted Use NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Daratumumab injection 08.02.04 Restricted Use NICE TA454 (not recommended): Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
Daratumumab injection 08.02.04 Restricted Use NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Darbepoetin alfa 09.01.03 Restricted Use NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Darvadstrocel injection 01.05 Non Formulary NICE TA556 (not recommended): Darvadstrocel for treating complex perianal fistulas in Crohn’s disease
Dasabuvir 05.03.03.02 Restricted Use NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Dasatinib 08.01.05 Restricted Use NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Dasatinib 08.01.05 Restricted Use NICE TA241: CML where treatment with imatinib has failed
Dasatinib 08.01.05 Restricted Use NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Decitabine 08.01.03 Non Formulary NICE TA270 (not recommended): Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal)
Degarelix 08.03.04.02 Restricted Use NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab 06.06.02 Restricted Use NICE TA265: Bone metastases from solid tumours - denosumab: guidance
Denosumab 06.06.02 Restricted Use NICE TA204: Osteoporotic fractures - denosumab
Dexamethasone intravitreal implant 11.04.01 Restricted Use NICE TA349: Dexamethasone intravitreal implant for treating diabetic macular oedema
Dexamethasone intravitreal implant 11.04.01 Restricted Use NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion
Dexamethasone intravitreal implant 11.04.01 Restricted Use NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
Dexamfetamine 04.04 Formulary NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents
Dimethyl fumarate 08.02.04 Restricted Use NICE TA320: Dimethyl fumarate for multiple sclerosis
Dimethyl fumarate 13.05.03 Non Formulary NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
Dinutuximab beta injection 08.02.04 Non Formulary NICE TA538: Dinutuximab beta for treating neuroblastoma
Dipyridamole 02.09 Formulary NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Docetaxel 08.01.05 Restricted Use NICE TA109: Breast cancer (early) - docetaxel
Docetaxel 08.01.05 Restricted Use NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Donepezil 04.11 Restricted Use NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Doxorubicin pegylated liposomal 08.01.02 Restricted Use NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Dronedarone 02.03.02 Formulary NICE TA197: Atrial fibrillation - dronedarone
Dupilumab injection 13.05.01 Restricted Use NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis
Durvalumab 08.01.05 Formulary NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
Eculizumab 09.01.03 Formulary NICE HST1: Eculizumab for treating atypical haemolytic uraemic syndrome
Edoxaban 02.08.02 Restricted Use NICE TA355:Edoxaban for preventing stroke/systemic embolism in non‑valvular atrial fibrillation
Edoxaban 02.08.02 Restricted Use NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Elbasvir + Grazoprevir 05.03.03.02 Restricted Use NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
Eliglustat 09.08.01 Formulary NICE HST5: Eliglustat for treating type 1 Gaucher disease
Elosulfase Alfa 09.08.01 Non Formulary NICE HST2: Elosulfase alfa for treating mucopolysaccharidosis type IVa (Morquio A Syndrome)
Elotuzumab 08.01.05 Non Formulary NICE TA434 (not recommended): Elotuzumab for previously treated multiple myeloma (terminated appraisal)
Eltrombopag 09.01.04 Restricted Use NICE TA293: Eltrombopag for treating chronic ITP
Eltrombopag 09.01.04 Restricted Use NICE TA382 (not recommended): Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal)
Eluxadoline 01.04.02 Formulary NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea
Empagliflozin 06.01.02.03 Restricted Use NICE TA336: Empagliflozin for type 2 diabetes
Empagliflozin 06.01.02.03 Restricted Use NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Encorafenib caps 08.01.05 Restricted Use NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Entecavir 05.03.03.01 Formulary NICE TA153: Hepatitis B (chronic) - etecavir
Enzalutamide 08.03.04.02 Formulary NICE TA316: Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen
Enzalutamide 08.03.04.02 Formulary NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Enzalutamide 08.03.04.02 Formulary NICE TA580: Enzalutamide for hormone-relapsed non-metastatic prostate cancer
Epoetin alfa 09.01.03 Restricted Use NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Epoetin alfa 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Epoetin beta 09.01.03 Restricted Use NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Epoetin theta 09.01.03 Non Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Epoetin zeta 09.01.03 Non Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Eribulin 08.01.05 Restricted Use NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Eribulin 08.01.05 Restricted Use NICE TA515 (not recommended): Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
Erlotinib 08.01.05 Restricted Use NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Erlotinib 08.01.05 Restricted Use NICE TA227 (not recommended): Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
Erlotinib 08.01.05 Restricted Use NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Ertugliflozin tabs 06.01.02.03 Formulary NICE TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
Ertugliflozin tabs 06.01.02.03 Formulary NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
Etanercept 13.05.03 Restricted Use NICE TA103: Etanercept and efalizumab for the treatment of adults with psoriasis
Etanercept 13.05.03 Restricted Use NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Etanercept 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor
Etanercept 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis
Etanercept 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA
Etanercept 10.01.03 Non Formulary NICE TA35: Adult psoriasis
Etanercept 10.01.03 Non Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Non Formulary NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor
Etanercept 10.01.03 Non Formulary NICE TA199: Psoriatic arthritis
Etanercept 10.01.03 Non Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etelcalcetide 09.05.01.02 Restricted Use NICE TA448: Etelcalcetide for treating secondary hyperparathyroidism
Everolimus 08.02.02 Non Formulary NICE TA348 (not recommended): Everolimus for preventing organ rejection in liver transplantation
Everolimus 08.02.02 Non Formulary NICE TA481 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in adults
Everolimus 08.02.02 Non Formulary NICE TA482 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in children and young people
Everolimus 08.01.05 Restricted Use NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Everolimus 08.01.05 Restricted Use NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Everolimus 08.01.05 Restricted Use NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Everolimus 08.01.05 Restricted Use NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Evolocumab 02.12 Restricted Use NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Ex vivo expanded autologous human corneal epithelial cells containing stem cells 17 Non Formulary NICE TA467: Holoclar for treating limbal stem cell deficiency after eye burns
Exemestane 08.03.04.01 Restricted Use NICE TA112: Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
Ezetimibe 02.12 Restricted Use NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Febuxostat 10.01.04 Restricted Use NICE TA164: Hyperuricaemia - febuxostat
Fingolimod 08.02.04 Formulary NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine 08.01.03 Formulary NICE TA119 (not recommended): Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia
Fludarabine 08.01.03 Formulary NICE TA29: Fludarabine for B-cell chronic lymphocytic leukaemia
Fluocinolone acetonide intravitreal implant 11.04.01 Restricted Use NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy
Fulvestrant 08.03.04.01 Restricted Use NICE TA239 (not recommended): Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Fulvestrant 08.03.04.01 Restricted Use NICE TA503 (not recommended): Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
Galantamine 04.11 Formulary NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Galantamine modified release 04.11 Restricted Use NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Gefitinib 08.01.05 Restricted Use NICE TA374 (not recommended): Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Gefitinib 08.01.05 Restricted Use NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
Gemcitabine 08.01.03 Formulary NICE TA116: Breast cancer - gemcitabine
Gemcitabine 08.01.03 Formulary NICE TA25: Pancreatic cancer - gemcitabine
Gemcitabine 08.01.03 Formulary NICE TA389 (topotecan, trabectedin and gemcitabine NOT recommended): Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Gemtuzumab ozogamicin injection 08.02.03 Non Formulary NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
Glatiramer acetate 08.02.04 Restricted Use NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Glecaprevir + Pibrentasvir 05.03.03.02 Formulary NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma - carmustine implants and temozolomide
Golimumab 10.01.03 Restricted Use NICE TA220: psoriatic arthritis
Golimumab 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Golimumab 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Restricted Use NICE TA225: Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs
Golimumab 10.01.03 Restricted Use NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
Golimumab 01.05.03 Restricted Use NICE TA329: NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Guselkumab 13.05.03 Non Formulary NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis
Ibandronic Acid 150mg tablets 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Ibandronic Acid IV injection 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Ibrutinib 08.01.05 Restricted Use NICE TA429 : Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Ibrutinib 08.01.05 Restricted Use NICE TA437 (not recommended): Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)
Ibrutinib 08.01.05 Restricted Use NICE TA452 (not recommended): Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)
Ibrutinib 08.01.05 Restricted Use NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Ibrutinib 08.01.05 Restricted Use NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Idelalisib 08.01.05 Restricted Use NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia
Idelalisib 08.01.05 Restricted Use NICE TA328 (not recommended): Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal)
Idelalisib 08.01.05 Restricted Use NICE TA469 (not recommended): Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal)
Imatinib tabs 08.01.05 Restricted Use NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Imatinib tabs 08.01.05 Restricted Use NICE TA209 (not recommended): Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Imatinib tabs 08.01.05 Restricted Use NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
Imatinib tabs 08.01.05 Restricted Use NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Imatinib tabs 08.01.05 Restricted Use NICE TA425 (not recommended): Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Imatinib tabs 08.01.05 Restricted Use NICE TA70: Imatinib for chronic myeloid leukaemia
Infliximab 13.05.03 Restricted Use NICE TA134: Infliximab for the treatment of adults with psoriasis
Infliximab 01.05.03 Non Formulary NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Non Formulary NICE TA187: Crohns disease - infliximab & adalimumab
Infliximab 01.05.03 Non Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Infliximab 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Infliximab 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis
Infliximab 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor)
Infliximab 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Infliximab 01.05.03 Restricted Use NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Restricted Use NICE TA187: Crohns disease - infliximab & adalimumab
Infliximab 01.05.03 Restricted Use NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Inositol Nicotinate 02.06.04 Non Formulary NICE TA223 (not recommended): Intermittent claudication drugs
Inotersen injection 04.13 Restricted Use NICE HST9: Inotersen for treating hereditary transthyretin amyloidosis
Inotuzumab ozogamicin injection 08.01.05 Non Formulary NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
Interferon Alfa 08.02.04 Restricted Use NICE TA75: Interferon Alfa - Chronic Hepatitis C
Interferon beta-1a 08.02.04 Restricted Use NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon beta-1a 08.02.04 Non Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon beta-1b 08.02.04 Non Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon beta-1b 08.02.04 Non Formulary NICE TA527 (not recommended): Beta interferons and glatiramer acetate for treating multiple sclerosis
Ipilimumab 08.01.05 Restricted Use NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Restricted Use NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Restricted Use NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Ipilimumab 08.01.05 Restricted Use NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
Irinotecan Hydrochloride 08.01.05 Restricted Use NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Irinotecan pegylated liposomal 08.01.05 Non Formulary NICE TA440 (not recommended): Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
Ivabradine 02.06.03 Restricted Use NICE TA267: Ivabradine for treating chronic heart failure
Ixazomib 08.01.05 Formulary NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Ixekizumab injection 10.01.03 Restricted Use NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Ixekizumab injection 13.05.03 Restricted Use NICE TA442 : Ixekizumab for treating moderate to severe plaque psoriasis
Lapatinib 08.01.05 Restricted Use NICE TA257 (lapatinib not recommended): Lapatinib or trastuzumab in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Ledipasvir + Sofosbuvir 05.03.03.02 Restricted Use NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C
Lenalidomide 08.02.04 Restricted Use NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy
Lenalidomide 08.02.04 Restricted Use NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Lenalidomide 08.02.04 Restricted Use NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Lenalidomide 08.02.04 Restricted Use NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
Lenalidomide 08.02.04 Restricted Use NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma
Lenvatinib caps 08.01.05 Formulary NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Lenvatinib caps 08.01.05 Formulary NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
Lenvatinib caps 08.01.05 Formulary NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Lesinurad 10.01.04 Non Formulary NICE TA506 (not recommended): Lesinurad for treating chronic hyperuricaemia in people with gout
Letrozole 08.03.04.01 Formulary NICE TA112: Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
Loxapine inhalation 04.02.01 Non Formulary NICE TA286 (not recommended): Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal)
Lubiprostone 01.06.07 Restricted Use NICE TA318: Lubiprostone for treating chronic idiopathic constipation
Lumacaftor + Ivacaftor 03.07 Non Formulary NICE TA398 (not recommended): Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
Lutetium (177Lu) oxodotreotide injection 08.01.05 Formulary NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
Mannitol inhalation 03.07 Restricted Use NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation
Mepolizumab 03.04.02 Restricted Use NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma
Methadone 04.10.03 Formulary NICE TA114: Drug misuse - methadone and buprenorphine
Methylnaltrexone 01.06.06 Non Formulary NICE TA277 (not recommended): Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal)
Methylnaltrexone 01.06.06 Non Formulary NICE TA468: Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal)
Methylphenidate 04.04 Non Formulary NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents
Methylphenidate Hydrochloride 04.04 Non Formulary NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents
Methylphenidate Hydrochloride 04.04 Non Formulary NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents
Methylphenidate Hydrochloride 04.04 Restricted Use NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents
Methylphenidate Hydrochloride 04.04 Non Formulary NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents
Methylphenidate Hydrochloride 04.04 Restricted Use NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents
Methylphenidate Hydrochloride 04.04 Restricted Use NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents
Methylphenidate Hydrochloride MR 04.04 Non Formulary NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents
Midostaurin 08.01.05 Non Formulary NICE TA523: Midostaurin for untreated acute myeloid leukaemia
Mifamurtide 08.02.04 Restricted Use NICE TA235: Osteosarcoma - mifamurtide: guidance
Milrinone 02.01.02 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for overactive bladder
Modafinil 04.04 Formulary NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents
Mycophenolate mofetil 08.02.01 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Mycophenolate sodium 08.02.01 Non Formulary NICE TA481 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in adults
Mycophenolate sodium 08.02.01 Non Formulary NICE TA482 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in children and young people
Naftidrofuryl oxalate 02.06.04 Formulary NICE TA223: Intermittent claudication drugs
Nalmefene 04.10.01 Formulary NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence
Naloxegol 01.06.06 Restricted Use NICE TA345: Naloxegol for treating opioid‑induced constipation
Naltrexone 04.10.03 Formulary NICE TA115: Drug misuse - naltrexone
Naltrexone + Bupropion 04.05.01 Non Formulary NICE TA494 (not recommended): Naltrexone–bupropion for managing overweight and obesity
Natalizumab 08.02.04 Restricted Use NICE TA127: Multiple sclerosis - natalizumab
Necitumumab 08.01.05 Non Formulary NICE TA411 (not recommended): Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
Nilotinib 08.01.05 Restricted Use NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Nilotinib 08.01.05 Restricted Use NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML
Nilotinib 08.01.05 Restricted Use NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Nilotinib 08.01.05 Restricted Use NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Nintedanib 03.11 Restricted Use NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis
Nintedanib 08.02.04 Restricted Use NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
Nintedanib 03.11 Restricted Use NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
Niraparib caps 08.01.05 Non Formulary NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
Nivolumab injection 08.02.04 Restricted Use NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Nivolumab injection 08.02.04 Restricted Use NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Nivolumab injection 08.02.04 Restricted Use NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Nivolumab injection 08.02.04 Restricted Use NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Nivolumab injection 08.02.04 Restricted Use NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
Nivolumab injection 08.02.04 Restricted Use NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
Nivolumab injection 08.02.04 Restricted Use NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Nivolumab injection 08.02.04 Restricted Use NICE TA530 (not recommended): Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
Nivolumab injection 08.02.04 Restricted Use NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
Nivolumab injection 08.02.04 Restricted Use NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
Obeticholic acid 01.09.01 Formulary NICE TA443 : Obeticholic acid for treating primary biliary cholangitis
Obinutuzumab 08.02.03 Restricted Use NICE TA343: Obinutuzumab with chlorambucil for CLL
Obinutuzumab 08.02.03 Restricted Use NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Obinutuzumab 08.02.03 Restricted Use NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma
Ocrelizumab injection 08.02.04 Formulary NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
Ocrelizumab injection 08.02.04 Formulary NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis
Ocriplasmin intravitreal injection 11.08.02 Restricted Use NICE TA297: Ocriplasmin for treating vitreomacular traction
Ofatumumab 08.02.03 Restricted Use NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia
Ofatumumab 08.02.03 Restricted Use NICE TA202 (not recommended): Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab
Ofatumumab 08.02.03 Restricted Use NICE TA469 (not recommended): Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal)
Ofatumumab 08.02.03 Restricted Use NICE TA470 (not recommended): Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal)
Olaparib 08.02.04 Restricted Use NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
Olaratumab 08.01.05 Formulary NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
Omalizumab 03.04.02 Restricted Use NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
Omalizumab 03.04.02 Restricted Use NICE TA278: Omalizumab for treating allergic asthma
Ombitasvir + paritaprevir + ritonavir 05.03.03.02 Restricted Use NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Oseltamivir 05.03.04 Restricted Use NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza
Oseltamivir 05.03.04 Restricted Use NICE TA158 (amantadine NOT recommended): Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Osimertinib 08.02.04 Formulary NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
Oxaliplatin 08.01.05 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Paclitaxel 08.01.05 Restricted Use NICE TA108 (not recommended): Paclitaxel for the adjuvant treatment of early node-positive breast cancer
Paclitaxel 08.01.05 Restricted Use NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Paclitaxel 08.01.05 Restricted Use NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
Paclitaxel - Albumin Bound Formulation 08.01.05 Restricted Use NICE TA362 (not recommended): Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal)
Paclitaxel - Albumin Bound Formulation 08.01.05 Restricted Use NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Padeliporfin injection 08.03.04.02 Non Formulary NICE TA546 (not recommended): Padeliporfin for untreated localised prostate cancer
Palbociclib 08.01.05 Restricted Use NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Panitumumab 08.01.05 Restricted Use NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Panitumumab 08.01.05 Restricted Use NICE TA240 (not recommended): Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)
Panitumumab 08.01.05 Restricted Use NICE TA242 (not recommended): Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy
Panobinostat 08.01.05 Restricted Use NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
Pazopanib 08.01.05 Restricted Use NICE TA215: Pazopanib in renal cell cancer
Pegaspargase 08.01 Restricted Use NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
Peginterferon Alfa 08.02.04 Restricted Use NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Peginterferon Alfa 08.02.04 Restricted Use NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa 08.02.04 Restricted Use NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa 08.02.04 Restricted Use NICE TA96: Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
Peginterferon Alfa 08.02.04 Restricted Use NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
Peginterferon Alfa 08.02.04 Formulary NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa 08.02.04 Formulary NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
Pegloticase 20 Non Formulary NICE TA291: Pegloticase not recommended for severe chronic gout
Pembrolizumab injection 08.01.05 Formulary NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pembrolizumab injection 08.01.05 Formulary NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pembrolizumab injection 08.01.05 Formulary NICE TA357: Pembrolizumab for melanoma after ipilimumab
Pembrolizumab injection 08.01.05 Formulary NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
Pembrolizumab injection 08.01.05 Formulary NICE TA522: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Pembrolizumab injection 08.01.05 Formulary NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab injection 08.01.05 Formulary NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Pembrolizumab injection 08.01.05 Formulary NICE TA447: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab injection 08.01.05 Formulary NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
Pembrolizumab injection 08.01.05 Formulary NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Pemetrexed 08.01.03 Restricted Use NICE TA135: Mesothelioma - pemetrexed disodium
Pemetrexed 08.01.03 Restricted Use NICE TA190: Lung cancer (non-small-cell, maintenance) - pemetrexed
Pemetrexed 08.01.03 Restricted Use NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Pemetrexed 08.01.03 Restricted Use NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Pemetrexed 08.01.03 Restricted Use NICE TA124 (not recommended): Pemetrexed for locally advanced or metastatic non-small-cell lung cancer
Pentoxifylline 02.06.04 Formulary NICE TA223 (not recommended): Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
Pertuzumab injection 08.01.05 Restricted Use NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Pertuzumab injection 08.01.05 Restricted Use NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pertuzumab injection 08.01.05 Restricted Use NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
Pimecrolimus 1% cream 13.05.03 Restricted Use NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Pirfenidone 03.11 Restricted Use NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis
Pixantrone 08.01.02 Formulary NICE TA306: Pixantrone monotherapy
Pomalidomide 08.02.04 Restricted Use NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Ponatinib 08.01.05 Restricted Use NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Prasugrel 02.09 Restricted Use NICE TA317: Acute coronary syndrome - prasugrel
Prucalopride 01.06.07 Restricted Use NICE TA211: Constipation (women) - prucalopride
Radium-223 dichloride 08.03.04.02 Restricted Use NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
Raloxifene 06.04.01.01 Restricted Use NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Raloxifene 06.04.01.01 Restricted Use NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Ramucirumab 08.01.05 Non Formulary NICE TA403 (not recommended): Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
Ramucirumab 08.01.05 Non Formulary NICE TA378 (not recommended): Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy
Ranibizumab intravitrial injection 11.08.02 Restricted Use NICE TA274: Ranibizumab for treating diabetic macular oedema
Ranibizumab intravitrial injection 11.08.02 Restricted Use NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (wAMD)
Ranibizumab intravitrial injection 11.08.02 Restricted Use NICE TA283: Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
Ranibizumab intravitrial injection 11.08.02 Restricted Use NICE TA298: Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
Regorafenib tab 08.01.05 Formulary NICE TA334 (not recommended): Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal)
Regorafenib tab 08.01.05 Formulary NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Regorafenib tab 08.01.05 Formulary NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
Regorafenib tab 08.01.05 Formulary NICE TA514 (not recommended): Regorafenib for previously treated advanced hepatocellular carcinoma
Reslizumab 03.04.02 Non Formulary NICE TA479: Reslizumab for treating severe eosinophilic asthma
Retigabine 04.08.01 Formulary NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
Ribavirin 05.03.05 Restricted Use NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Restricted Use NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribavirin 05.03.05 Restricted Use NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Restricted Use NICE TA300: Hepatitis C - peginterferon alfa and ribavirin in children and young people
Ribociclib 08.01.05 Formulary NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Rifaximin 05.01.07 Restricted Use NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
Riluzole 04.09.03 Restricted Use NICE TA20: Motor neurone disease - riluzole
Risedronate 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Rituximab 08.02.03 Restricted Use NICE TA137: Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma
Rituximab 08.02.03 Restricted Use NICE TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia
Rituximab 08.02.03 Restricted Use NICE TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
Rituximab 08.02.03 Restricted Use NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma
Rituximab 08.02.03 Restricted Use NICE TA226: Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma
Rituximab 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Rituximab 10.01.03 Restricted Use NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Rivaroxaban 02.08.02 Restricted Use NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults
Rivaroxaban 02.08.02 Restricted Use NICE TA265: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Rivaroxaban 02.08.02 Restricted Use NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Rivaroxaban 02.08.02 Restricted Use NICE TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
Rivaroxaban 02.08.02 Restricted Use NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Rivastigmine 04.11 Restricted Use NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Roflumilast 03.03.03 Formulary NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease
Romiplostim 09.01.04 Restricted Use NICE TA221: Thrombocytopenic purpura - romiplostim
Ruxolitinib 08.01.05 Restricted Use NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Ruxolitinib 08.01.05 Restricted Use NICE TA356 (not recommended): Ruxolitinib for treating polycythaemia vera (terminated appraisal)
Sacubitril + valsartan 02.05.05.02 Restricted Use NICE TA388: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
Sacubitril valsartan 02.05.05.02 Non Formulary NICE TA388: Sacubitril valsartan for heart failure (updated 16/7/16 to include adoption resources)
Sarilumab 10.01.03 Formulary NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab 10.01.03 Restricted Use
Secukinumab 10.01.03 Restricted Use NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Secukinumab 10.01.03 Restricted Use NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Secukinumab 13.05.03 Restricted Use NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis
Secukinumab 13.05.03 Restricted Use NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Simeprevir 05.03.03.02 Restricted Use NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C
Simeprevir 05.03.03.02 Restricted Use NICE TA361 (not recommended): Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal)
Sipuleucel- T 20 Formulary NICE TA322: Sipuleucel-T for prostate cancer
Sirolimus 08.02.02 Formulary NICE TA481 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in adults
Sirolimus 08.02.02 Formulary NICE TA482 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in children and young people
Sofosbuvir 05.03.03.02 Restricted Use NICE TA330: Sofosbuvir for treating chronic hepatitis C
Sofosbuvir + Velpatasvir 05.03.03.02 Restricted Use NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
Sofosbuvir + Velpatasvir + Voxilaprevir 05.03.03.02 Restricted Use NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
Somatropin 06.05.01 Restricted Use NICE TA64: Human growth hormone (somatropin) in adults with growth hormone deficiency
Somatropin 06.05.01 Restricted Use NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children
Sorafenib tabs 08.01.05 Restricted Use NICE TA178 (not recommended): Bevacizumab (1st line), sorafenib, sunitinib (2nd line) and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma
Sorafenib tabs 08.01.05 Restricted Use NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Sorafenib tabs 08.01.05 Restricted Use NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Sunitinib 08.01.05 Restricted Use NICE TA179: Gastrointestinal stromal tumours - sunitinib
Sunitinib 08.01.05 Restricted Use NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Sunitinib 08.01.05 Restricted Use NICE TA178 (not recommended): Bevacizumab (1st line), sorafenib, sunitinib (2nd line) and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma
Sunitinib 08.01.05 Restricted Use NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Tacrolimus 08.02.02 Restricted Use NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Tacrolimus 08.02.02 Restricted Use NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Tacrolimus 08.02.02 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Tacrolimus 08.02.02 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Tacrolimus 08.02.02 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Tacrolimus 08.02.02 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Tacrolimus 08.02.02 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Tacrolimus 08.02.02 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Tacrolimus modified release 08.02.02 Formulary NICE TA481 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in adults
Tacrolimus modified release 08.02.02 Formulary NICE TA482 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in children and young people
Tacrolimus modified release 08.02.02 Formulary NICE TA481 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in adults
Tacrolimus modified release 08.02.02 Formulary NICE TA482 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in children and young people
Tacrolimus ointment 13.05.03 Restricted Use NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Tadalafil (10mg, 20mg) 07.04.05 Restricted Use NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal)
Tadalafil (2.5mg, 5mg) 07.04.05 Non Formulary NICE TA273 (not recommended): Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal)
Talimogene laherparepvec 08.01.05 Restricted Use NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
Tamoxifen 08.03.04.01 Formulary NICE TA112: Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
Tegafur with Uracil 08.01.03 Non Formulary NICE TA61: capecitabine and tegafur with uracil for metastatic colorectal cancer
Telaprevir 05.03.03.02 Non Formulary NICE TA252: Telaprevir in hepatitis C
Telbivudine 05.03.03.01 Non Formulary NICE TA154 (not recommended): Telbivudine for the treatment of chronic hepatitis B
Temozolomide 08.01.05 Restricted Use NICE TA121: Glioma (newly diagnosed and high grade)
Temozolomide 08.01.05 Restricted Use NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
Temsirolimus 08.01.05 Non Formulary NICE TA178 (not recommended): Bevacizumab (1st line), sorafenib, sunitinib (2nd line) and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma
Temsirolimus 08.01.05 Non Formulary NICE TA207 (not recommended): Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal)
Tenofovir disproxil 05.03.01 Formulary NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Teriflunomide 08.02.04 Restricted Use NICE TA405:Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Teriflunomide 08.02.04 Restricted Use NICE TA303: Teriflunomide for relapsing remitting MS
Teriparatide 06.06.01 Formulary NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Thalidomide 08.02.04 Restricted Use NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Ticagrelor 02.09 Restricted Use NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
Ticagrelor 02.09 Restricted Use NICE TA236: Ticagrelor for the treatment of acute coronary syndromes
Tildrakizumab 13.05.03 Non Formulary NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis
Tisagenlecleucel cells dispersion for infusion 08.01.05 Non Formulary NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
Tivozanib 08.01.05 Formulary NICE TA512: Tivozanib for treating advanced renal cell carcinoma
Tobramycin inhaler 05.01.04 Non Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Tocilizumab 10.01.03 Restricted Use NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis
Tocilizumab 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Tocilizumab 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Tocilizumab 10.01.03 Restricted Use NICE TA238: Tocilizumab for the treatment of systemic juvenile idiopathic arthritis
Tocilizumab 10.01.03 Restricted Use NICE TA518: Tocilizumab for treating giant cell arteritis
Tofacitinib tabs 10.01.03 Formulary NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
Tofacitinib tabs 10.01.03 Formulary NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Tofacitinib tabs 01.05.03 Non Formulary NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
Tolvaptan 06.05.02 Restricted Use NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan
Topotecan 08.01.05 Restricted Use NICE TA184: Lung cancer (small-cell) - topotecan
Topotecan 08.01.05 Restricted Use NICE TA183: Cervical cancer (recurrent) - topotecan
Topotecan 08.01.05 Restricted Use NICE TA389 (not recommended): Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trabectedin 08.01.05 Restricted Use NICE TA185: Soft tissue sarcoma - trabectedin
Trabectedin 08.01.05 Restricted Use NICE TA389 (not recommended): Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trametinib tabs 08.01.05 Restricted Use NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Trastuzumab 08.01.05 Restricted Use NICE TA257: Lapatinib or trastuzumab in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Trastuzumab 08.01.05 Restricted Use NICE TA34: Breast cancer - trastuzumab
Trastuzumab 08.01.05 Restricted Use NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab emtansine 08.01.05 Restricted Use NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Trifluridine + tipiracil 08.01.03 Restricted Use NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Ustekinumab 01.05.03 Formulary NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Ustekinumab 10.01.03 Restricted Use NICE TA340: Ustekinumab for treating active psoriatic arthritis
Ustekinumab 13.05.03 Restricted Use NICE TA340: Ustekinumab for treating active psoriatic arthritis
Ustekinumab 13.05.03 Restricted Use NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis
Ustekinumab 13.05.03 Restricted Use NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Vandetanib tabs 08.01.05 Non Formulary NICE TA550 (not recommended): Vandetanib for treating medullary thyroid cancer
Varenicline 04.10.02 Formulary NICE TA123: Varenicline
Vemurafenib 08.01.05 Restricted Use NICE TA269: Vemurafenib for treating malignant melanoma
Venetoclax tabs 08.01.05 Restricted Use NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
Venetoclax tabs 08.01.05 Restricted Use NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
Verteporfin 11.08.02 Restricted Use NICE TA68: Photodynamic therapy for age related macular degeneration
Vinflunine 08.01.04 Non Formulary NICE TA272 (not recommended): Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine
Vismodegib 08.01.05 Restricted Use NICE TA489 (not recommended): Vismodegib for treating basal cell carcinoma
Vortioxetine 04.03.03 Formulary NICE TA367: Vortioxetine for treating major depressive episodes
Zanamivir inhalation 05.03.04 Restricted Use NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza
Zanamivir inhalation 05.03.04 Restricted Use NICE TA158 (amantadine NOT recommended): Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Zoledronic Acid 06.06.02 Restricted Use NICE TA464: Bisphosphonates for treating osteoporosis
Zolpidem 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Zopiclone 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
North Central London